August 21, 2014 6:39 AM ET


Company Overview of MedImmune, LLC

Company Overview

MedImmune, LLC, a biotechnology company, engages in the research and exploration of products in therapeutic areas, including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic diseases; oncology; neuroscience; and infection and vaccines. The company products include Synagis (palivizumab), a monoclonal antibody to prevent lower respiratory tract disease caused by respiratory syncytial virus in children; FluMist Quadrivalent, an influenza vaccine for protection against influenza A and B; and Trivalent FluMist, a nasally-administered live attenuated influenza vaccine. It serves customers globally. The company was formerly known as Molecular Vaccines, Inc. and changed its ...

One MedImmune Way

Gaithersburg, MD 20878

United States

Founded in 1988





Key Executives for MedImmune, LLC

Chief Operating Officer
Vice President
Executive Vice President of Legal Affairs
Age: 49
Senior Vice President of Biopharmaceutical Development
Age: 59
Vice President and Head of Medical & Scientific Affairs - Infectious Disease
Age: 67
Compensation as of Fiscal Year 2014.

MedImmune, LLC Key Developments

Advaxis, Inc. and MedImmune Collaborate on Immuno-Oncology Combination Clinical Trial

Advaxis, Inc. entered into a clinical trial collaboration with MedImmune. The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. MEDI4736 is designed to counter the tumour's immune-evading tactics by blocking a signal that helps tumours avoid detection, while ADXS-HPV enhances the ability of immune cells to combat the tumour. Preclinical evidence suggests that the combination of ADXS-HPV with a checkpoint inhibitor, such as MEDI4736, can enhance overall anti-tumour response. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted.

MedImmune, LLC Initiates Phase I Clinical Studies with MEDI8897

AIMM Therapeutics announced that its partner MedImmune, LLC has initiated phase I clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children. MEDI8897 originated from AIMM's D25 antibody. Under the terms of their partnering agreement, AIMM will receive a non-disclosed milestone payment from MedImmune. D25 was developed from immortalized B cells of an individual exposed to RSV utilizing AIMM's proprietary antibody technology platform. Preclinical studies have shown that D25 neutralizes RSV with high efficiency by recognizing a unique epitope on the prefusion structure of the F protein expressed on the virus coat.

ADC Therapeutics and MedImmune Announces Update on Joint Venture

ADC Therapeutics announced that it has selected its first IND candidate under its joint development agreement with MedImmune. This follows the October 2013 announcement in which MedImmune entered into a collaboration agreement with ADC Therapeutics to jointly develop two of ADCT's antibody-drug conjugate programs in preclinical development. ADCT-401 targets Prostate-Specific Membrane Antigen (PSMA) a cell-surface antigen specifically expressed by prostate cancer cells. ADCT-401 comprises an anti-PSMA monoclonal antibody coupled with a pyrrolobenzodiazepine (PBD) warhead using a proprietary linker licensed from London-based Spirogen, a wholly owned subsidiary of MedImmune. Initial clinical studies will focus on hormone-refractory prostate cancer and an IND filing is anticipated in 2015. The PSMA-specific J591 antibody in ADCT-401 was developed by Dr. Neil H. Bander, the Bernard & Josephine Chaus Professor of Urologic Oncology and Director of Urological Oncology Research at the Weill-Cornell Medical College, New York. Dr. Bander is also Chairman of ADCT's Scientific Advisory Board. PSMA is a cell-surface antigen expressed by virtually all prostate cancer cells, including metastases, and also in the blood vessels that feed many other tumor types, but is rarely expressed in normal cells. This will be ADCT's second ADC program into the clinic from its pipeline of eleven programs with an IND filing expected in the first of these programs by the end of the year 2014. The pre-clinical development of ADCT-401 is being managed by a team of scientists based in laboratories at the Queen Mary Bioenterprises Innovation Centre, London which, being co-located with Spirogen, enables close co-operation between the two groups.

Similar Private Companies By Industry

Company Name Region
Tutela Medicus, Inc. United States
Pinnacle Biologics, Inc. United States
Nodality, Inc. United States
Bimini Technologies LLC United States
Toma Biosciences, Inc. United States

Recent Private Companies Transactions

October 15, 2013
ADC Products Ltd.
August 26, 2013
Amplimmune, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MedImmune, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at